시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 오타코이드 및 관련 약물 시장 보고서(2025년)
Autacoids And Related Drug Global Market Report 2025
상품코드 : 1760473
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,222,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,993,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,765,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

오타코이드 및 관련 약물 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 2029년에는 6.1%의 연평균 성장률(CAGR)로 성장하여, 676억 4,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 노인 인구 증가, 만성 호흡기 질환 유병률 증가, 맞춤형 의료 채택, 신흥 국가의 건강 관리 접근 확대, 심혈관 장애 발생률 증가 등 여러 요인에 기인하고 있습니다. 이 기간의 주요 동향으로는 신약에 있어서의 인공지능의 통합, 이중작용 오타코이드의약품의 개발, 오타코이드 치료에의 바이오시밀러 채택, 셀프메디케이션과 일반용의약품(OTC)의 성장, 의약품제제에 있어서의 나노기술의 이용 등이 있습니다.

심혈관 질환의 유병률 증가는 향후 몇 년 동안 오타코이드 및 관련 약물 시장의 확대를 촉진할 것으로 예측됩니다. 다양한 질병이 포함됩니다. 심혈관 질환 증가는 주로 식생활의 혼란과 관련이 있으며, 포화 지방, 트랜스 지방, 첨가 당, 나트륨의 다량 섭취는 고혈압, 비만, 콜레스테롤 수치 상승의 원인이 됩니다. 그리고 이들은 모두 심장과 관련된 질병의 심각한 위험 요인입니다. 일산화질소, 엔도텔린, 프로스타사이클린이 관여하는 경로를 표적으로 하는 약제는 내피 기능의 회복, 혈관 확장의 촉진, 혈관 저항의 감소를 돕습니다. 2023년 12월 호주 보건복지연구원은 호주에서 관상동맥성 심장병(CHD)에 의한 의사 인증의 사망자 수가 2021년 1만 4,100명에서 2022년에는 1만 4,900명으로 증가했다고 보고했습니다.

자가면역약 및 관련약 시장의 주요 기업은 치료효과를 높이고, 부작용을 줄이고, 보다 정확하고 안전하게 새로운 알레르기성 질환이나 염증성 질환에 대처하기 위해 항히스타민제 등의 혁신적인 제품 개발에 집중하고 있습니다. 항히스타민제는 알레르기 반응시 면역계에서 방출되는 화학물질인 히스타민의 작용을 저해하는 약입니다. Pharmaceuticals는 빌라스틴을 일반용 의약품으로서 독일에서 출시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Autacoids and related drugs are biologically active substances produced by the body that regulate physiological functions locally, typically within specific tissues or organs. They play a role in inflammation, smooth muscle contraction, immune responses, and the regulation of blood flow. Autacoids exert their effects by binding to specific receptors on target cells, triggering signaling pathways that influence cellular activity.

The main types of autacoids and related drugs include histamines, prostaglandins, leukotrienes, serotonin, and bradykinin. Histamines are chemicals released during allergic reactions that lead to symptoms such as itching, swelling, and increased stomach acid. They are targeted in treatments for allergies and acid-related conditions. Drugs aimed at these autacoids can be administered through various routes, such as oral, injectable, topical, intranasal, and inhalation. These treatments are used for a range of applications, including cardiovascular disorders, inflammatory diseases, respiratory disorders, allergies, and gastrointestinal conditions. The primary end users of these treatments include hospitals, clinics, homecare settings, and pharmacies.

The autacoids and related drug market research report is one of a series of new reports from The Business Research Company that provides autacoids and related drug market statistics, including the autacoids and related drug industry global market size, regional shares, competitors with the autacoids and related drug market share, detailed autacoids and related drug market segments, market trends, and opportunities, and any further data you may need to thrive in the autacoids and related drug industry. This autacoids and related drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autacoids and related drug market size has grown strongly in recent years. It will grow from $50.15 billion in 2024 to $53.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to several factors, including the increasing prevalence of inflammatory diseases, a rising use of prostaglandins in obstetrics, widespread prescription of antihistamines, the expanding applications of serotonin agonists, and higher demand for migraine relief medications.

The autacoids and related drug market size is expected to see strong growth in the next few years. It will grow to $67.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to several factors, including the rising geriatric population, growing prevalence of chronic respiratory diseases, adoption of personalized medicine, expanding healthcare access in emerging economies, and the increasing incidence of cardiovascular disorders. Key trends during this period include the integration of artificial intelligence in drug discovery, the development of dual-action autacoid drugs, the adoption of biosimilars for autacoid treatments, growth in self-medication and over-the-counter (OTC) products, and the use of nanotechnology in drug formulation.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the autacoids and related drugs market in the coming years. Cardiovascular diseases encompass a range of disorders that impact the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. The rise in cardiovascular diseases is mainly linked to poor dietary habits, with high consumption of saturated fats, trans fats, added sugars, and sodium contributing to high blood pressure, obesity, and elevated cholesterol levels, all of which are significant risk factors for heart-related conditions. Autacoids and related drugs support cardiovascular health by modulating vascular tone and inflammation, both of which are critical in managing hypertension and heart failure. Agents that target pathways involving nitric oxide, endothelin, and prostacyclin aid in restoring endothelial function, promoting vasodilation, and reducing vascular resistance. For instance, in December 2023, the Australian Institute of Health and Welfare reported that the number of doctor-certified deaths due to coronary heart disease (CHD) in Australia rose from 14,100 in 2021 to 14,900 in 2022. Consequently, the increasing prevalence of cardiovascular diseases is fueling the growth of the autacoids and related drugs market.

Leading companies in the autacoids and related drugs market are concentrating on the development of innovative products, such as antihistamines, to enhance therapeutic effectiveness, reduce side effects, and address new allergic and inflammatory conditions with greater accuracy and safety. Antihistamines are medications that block the effects of histamine, a chemical released by the immune system during an allergic reaction. For example, in March 2023, Tiefenbacher Pharmaceuticals, a Germany-based pharmaceutical company, launched Bilastine as an over-the-counter (OTC) medication in Germany, representing a significant advancement in improving access to effective allergy treatments. The 20 mg Bilastine tablets offer a non-sedating, second-generation antihistamine solution for individuals experiencing allergic symptoms such as hay fever and urticaria.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, completed the acquisition of Escient Pharmaceuticals Inc. for approximately $750 million. This acquisition enables Incyte to expand its immunology portfolio and accelerate the development of novel treatments for pruritus and other inflammatory disorders by integrating Escient Pharmaceuticals' innovative pipeline of first-in-class, small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs). Escient Pharmaceuticals Inc., a US-based biotechnology company, is focused on developing novel therapeutics that target autacoid-related pathways.

Major players in the autacoids and related drug market are Sanofi S.A., Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Limited, EUROAPI S.A., Pfizer CentreOne, Cayman Chemical Company, Tokyo Chemical Industry Co. Ltd., Avanti Polar Lipids Inc., Kyowa Pharma Chemical Co. Ltd., Nicox S.A., Glentham Life Sciences Ltd., LGM Pharma Inc., chemBlink Inc., ZellBio GmbH, AquigenBio LLC, BOC Sciences Inc., Yarrow Chem Products Pvt. Ltd., LEBSA S.A., VDK NaturaSyn S.A., Enzo Life Sciences Inc.

North America was the largest region in the autacoids and related drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autacoids and related drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autacoids and related drugsmarket report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autacoids and related drug market consists of sales of biogenic amines, polypeptide autacoids, lipid-derived autacoids, and leukotrienes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autacoids And Related Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autacoids and related drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for autacoids and related drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autacoids and related drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Autacoids And Related Drug Market Characteristics

3. Autacoids And Related Drug Market Trends And Strategies

4. Autacoids And Related Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autacoids And Related Drug Growth Analysis And Strategic Analysis Framework

6. Autacoids And Related Drug Market Segmentation

7. Autacoids And Related Drug Market Regional And Country Analysis

8. Asia-Pacific Autacoids And Related Drug Market

9. China Autacoids And Related Drug Market

10. India Autacoids And Related Drug Market

11. Japan Autacoids And Related Drug Market

12. Australia Autacoids And Related Drug Market

13. Indonesia Autacoids And Related Drug Market

14. South Korea Autacoids And Related Drug Market

15. Western Europe Autacoids And Related Drug Market

16. UK Autacoids And Related Drug Market

17. Germany Autacoids And Related Drug Market

18. France Autacoids And Related Drug Market

19. Italy Autacoids And Related Drug Market

20. Spain Autacoids And Related Drug Market

21. Eastern Europe Autacoids And Related Drug Market

22. Russia Autacoids And Related Drug Market

23. North America Autacoids And Related Drug Market

24. USA Autacoids And Related Drug Market

25. Canada Autacoids And Related Drug Market

26. South America Autacoids And Related Drug Market

27. Brazil Autacoids And Related Drug Market

28. Middle East Autacoids And Related Drug Market

29. Africa Autacoids And Related Drug Market

30. Autacoids And Related Drug Market Competitive Landscape And Company Profiles

31. Autacoids And Related Drug Market Other Major And Innovative Companies

32. Global Autacoids And Related Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autacoids And Related Drug Market

34. Recent Developments In The Autacoids And Related Drug Market

35. Autacoids And Related Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기